Diabetes drug linked to pancreatitis admission, study finds

06/11/2013 | Daily Express (London)

Patients on incretin mimetics were at double the risk of being hospitalized for the treatment of pancreatitis compared with those taking other diabetes drugs, according to a review in the British Medical Journal. "The FDA and [European Medicines Agency] have both confirmed to the BMJ that their own analyses also show increased reporting or signals of pancreatic cancer with incretin mimetics. But they emphasise that this does not mean the relation is causal," researchers wrote.

View Full Article in:

Daily Express (London)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC